Results 211 to 220 of about 297,910 (307)
Abstract Background Visuospatial deficits in Parkinson's disease (PD) often precede dementia and complicate daily functioning. Alzheimer's disease (AD) pathology and α‐synuclein aggregation frequently co‐occur in PD, but their combined impact on cognition is unclear.
David Ledingham +8 more
wiley +1 more source
Persistent Tremor in Bipolar Disorder: A Case Report of Idiopathic Parkinson's Disease Superimposed on Lithium and Antipsychotic Effects. [PDF]
Jetter E, Valle D, Nolasco D, Carr B.
europepmc +1 more source
Reduced Dopamine Transporter Uptake in Dentatorubral‐Pallidoluysian Atrophy
Movement Disorders Clinical Practice, EarlyView.
Kei Okuba +3 more
wiley +1 more source
Abstract Objective Investigate the efficacy of immediate‐release (IR) amantadine in reducing the risk of peak‐dose dyskinesia in early Parkinson's disease (PD) as add‐on to levodopa. Background While the use of amantadine to manage dyskinesia in PD is well supported by controlled clinical trials, data on its efficacy in patients without motor ...
Olivier Rascol +106 more
wiley +1 more source
Are glutathionylated aldehyde reductases the missing piece of the "catecholaldehyde hypothesis" in Parkinson's disease? A medical hypothesis concerning the detoxification of 4-hydroxynonenal (HNE) and 3,4-dihydroxyphenylacetaldehyde (DOPAL). [PDF]
Rotondo R +11 more
europepmc +1 more source
Refractory Motor Complications: Towards a Pragmatic Definition
Movement Disorders Clinical Practice, EarlyView.
Georg Ebersbach, Tobias Warnecke
wiley +1 more source
Abstract Background Peripheral disease mechanisms such as immune dysregulation may contribute to Parkinson's disease (PD). To investigate interactions between common PD mutations and immune responses to environmental pathogens, we studied responses to Pseudomonas aeruginosa (P.
Julian R. Mark +8 more
wiley +1 more source
Dopamine and the Gut Microbiota: Interactions Within the Microbiota-Gut-Brain Axis and Therapeutic Perspectives. [PDF]
Barbu AC +10 more
europepmc +1 more source
Factors Associated with Early Discontinuation of Foslevodopa/Foscarbidopa in Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.
Keita Kakuda +7 more
wiley +1 more source

